Oticara’s Intranasal Steroid Cream Achieves Phase 2 Success in Post-Surgical Chronic Rhinosinusitis

Published On 2025-10-14 15:15 GMT | Update On 2025-10-14 15:15 GMT

Oticara’s intranasal steroid cream met primary endpoints in a phase 2 trial for post-surgical chronic rhinosinusitis (CRS), showing significant improvements in 4CSS and SNOT-22 scores by week 3. The in-office treatment provided rapid, durable symptom relief and was well-tolerated, with no severe adverse events reported.

The late-breaking presentation, delivered by Professor Anders Cervin, MD, PhD, FRACS, will highlight findings from the Phase 2 trial of Oticara’s proprietary nasal-mucosa-optimized steroid cream. The treatment is an Ear, Nose and Throat (ENT) physician-administered cream designed specifically for the nasal mucosa, with clinical data demonstrating single-dose, durable relief for hard-to-treat post-surgical CRS patients.

“We are honored to have been selected to present our recent clinical study results at AAO-HNSF,” said Chris Marich, Founder and Chief Executive Officer of Oticara. “We see a clear need for new options that can deliver durable benefits and reduce reliance on systemic steroids in hard-to-treat CRS patients with an easy-to-administer single-dose treatment.”

Full data from the Phase 2 OT-007B trial will be presented during the meeting and the scientific paper is undergoing peer review by the American Academy of Otolaryngology–Head and Neck Surgery Foundation.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Oticara’s Intranasal Steroid Cream Achieves Phase 2 Success in Post-Surgical Chronic Rhinosinusitis

Similar News

Tinnitus and Dizziness Linked to Higher Risk of Chronic and Recurrent Headaches, Study Finds

Depression Linked to Higher Risk of Sleep Apnea, NHANES Study Finds

Weight Gain and Obesity Strongly Linked to Higher Asthma Risk, Especially in Middle-Aged Adults, New Study Finds

Sotatercept Improves Early Pulmonary Arterial Hypertension Outcomes: NEJM

Could nasal sprays replace needles for delivering adrenaline to anaphylactic patients?

3% Hypertonic Saline Nasal Irrigation Eases Allergic Rhinitis Symptoms but Not Superior to Isotonic Saline: Study

Infants with Sleep-Disordered Breathing and Severe Laryngomalacia Face Higher Surgery Risk: Study Suggests